SPECTRUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1987-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.sppirx.com
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-02-04
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 201
- Registration Number
- NCT00606502
- Locations
- 🇺🇸
Donald Berdeaux, Great Falls, Montana, United States
🇦🇷Instituto Medico Especializado Alexander Fleming, Buenos Aires, Cuidad De Buenos Aires, Argentina
🇦🇷Policlinica Privada - Instituto de Medicina Nuclear, Bahia Blanca, Provincia De Buenos Aires, Argentina
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 812
- Registration Number
- NCT00598806
- Locations
- 🇺🇸
PharmaTrials, Inc., Hillsborough, New Jersey, United States
🇵🇱Samodzielny Publiczny Zakład Opieki Zdrowotnej w Pabianicach, Pabianice, Poland
🇺🇸Advanced Urology Medical Center Clinical Trials, Anaheim, California, United States
Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- Advanced Solid TumorsNon-Hodgkin's Lymphoma
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2013-05-10
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 12
- Registration Number
- NCT00558727
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Hudson-Webber Cancer Research Center, Detroit, Michigan, United States
🇺🇸University of Colorado Health Science Center, Aurora, Colorado, United States
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
- Conditions
- Metastatic Malignant Uveal Melanoma
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 54
- Registration Number
- NCT00506142
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Colorado, Denver, Denver, Colorado, United States
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 65
- Registration Number
- NCT00495079
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇩🇪University of Muenster, Muenster, Germany
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 802
- Registration Number
- NCT00461591
- Locations
- 🇺🇸
Urology of Virginia, PC, Virginia Beach, Virginia, United States
🇺🇸Delaware Valley Urology, LLC - Voorhees, Voorhees, New Jersey, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
- First Posted Date
- 2007-01-26
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 74
- Registration Number
- NCT00427219
- Locations
- 🇺🇸
Jay Young, MD, Laguna Hills, California, United States
🇺🇸Christopher Steidle, MD, Fort Wayne, Indiana, United States
🇺🇸Gregg Eure, MD, Virginia Beach, Virginia, United States
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
- Conditions
- Follicular LymphomaLymphoma, Follicular
- Interventions
- Drug: R-CVP
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 26
- Registration Number
- NCT00384111
- Locations
- 🇺🇸
Integrated Community Oncology Network, Jacksonville, Florida, United States
🇺🇸Wellstar-Northwest Georgia Oncology Centers, Marietta, Georgia, United States
🇺🇸Oncology Hematology Care Inc., Cincinnati, Ohio, United States
Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease
- Conditions
- TumorsHodgkins DiseaseNon-Hodgkins Lymphoma
- Interventions
- Drug: VLI
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 67
- Registration Number
- NCT00364676
- Locations
- 🇺🇸
Cancer Therapy and Research Center, San Antonio, Texas, United States
🇨🇦McGill Centre for Translational Research in Cancer-Jewish General Hospital Clinical Research Unit, Montreal, Quebec, Canada
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 68
- Registration Number
- NCT00322218
- Locations
- 🇺🇸
Research site, Detroit, Michigan, United States
🇬🇧Research Site, London, United Kingdom
🇰🇷Research Site, Yonsei, Seoul, Korea, Republic of